1. Introduction {#sec1}
===============

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and is the leading cause of mortality in patients ([@bib1]). An estimated half million new cases are diagnosed each year world-wide with disease burden highest in developing countries (85% of all cases) ([@bib3]).

It was reported that 40%--80% of HCC cases have a positive HCV infection ([@bib22]) and its highest incidence in the world was found in Egypt ([@bib16]).

A livin protein is a member of a large family of a related protein associated with tumor occurrence and development, called The inhibitors of apoptosis proteins (IAPs) which consists of 8 members, termed baculoviral IAP repeat containing (BIRC) 1--8. A BIRC7, also known as *Livin* ([@bib28]).

The *Livin* gene spans 4.6 kb on chromosome 20 at band q13. It is composed of six introns and seven exons. *Livin* protects cells from various pro-apoptotic stimuli by inhibiting the activity of caspase -3, -7 and -9, and it plays an important role in tumorigenesis and chemo resistance ([@bib15]).

*Livin* is rarely detected in normal adult tissues but highly expressed in cancerous tissues. It is thought that *Livin* protein expression may be an early event in the occurrence of HCC ([@bib18]).

*Yes-associated protein 1 (YAP1*) is a major downstream target of the Hippo-signaling pathway ([@bib19]). Regulation of the Hippo-signaling pathway is known to be mediated by phosphorylation and subcellular localization of *YAP1*. Activation of the Hippo-signaling pathway induces phosphorylation of *YAP1*, which prevents the translocation to the nucleus. When the Hippo-signaling pathway is inactivated, dephosphorylated *YAP1* is translocated to the nucleus where it interacts with transcription factors, eventually leading to the proliferation of cells to various organ systems ([@bib20]).

The aims of this study were to evaluate the expression levels of *Livin* gene and *YAP1* in HCV associated HCC patients and their association to other laboratory parameters as well as the correlation of their expression levels with the overall survival rate in the HCC patients.

2. Subjects and methods {#sec2}
=======================

This pilot study is a case-control study. It was done by cooperation of Biochemistry department, Faculty of Science, Menoufia University, Medical Biochemistry & Molecular Biology and Microbiology departments, Faculty of Medicine, Menoufia University between December 2017 and June 2018 and included 90 patients and 30 healthy controls.

After taking informed written consent from all subjects and approval of the Ethical Committee of Medical Research- Menoufia Faculty of Medicine, all patients were subjected to the following: Full history taking, General and clinical examination, Ultrasound (US) and C.T, laboratory investigations included: Complete liver function tests, Hepatitis markers for Hepatitis A Virus (HAV): IgM for recent infection. IgG for old infection, for Hepatitis B Virus (HBV): HBsAg, HBsAb, HB core Ab,HBeAg, HBe Ab. for Hepatitis C Virus: HCV-Ab, PCR. kidney function tests, tumor markers including Alpha fetoprotein (AFP) and carcinoembryonic antigen (CEA), Detection of gene expression by real time PCR. Patients with other types of hepatitis were excluded from the study after making Hepatitis markers mentioned before from medical reports. Subjects were classified into four groups: Group I: patients with Hepatocellular carcinoma on the top of chronic Hepatitis C untreated (30 patients). Group II: patients with chronic Hepatitis C untreated after investigation include + HCV Ab,CT, tumor markers (30 patients). Group III: patients with HCV who received treatment (30 patients) in the form of Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks. During treatment, they were closely monitored at week 2, week 4, week 8, and week 12 by laboratory studies including CBC, creatinine, AST, ALT, and total bilirubin.Group IV: apparently healthy control subjects (a blood bank donors) (30 subjects).

Blood samples: after overnight fasting ten ml of venous blood was obtained from each participantand divided into three parts. First part two ml was put in citrated tube for use in detection of prothrombin time and international normalized ratio (INR). The second part two ml was put in EDTA tubes for complete blood count and total RNA extraction to be used in determination of *Livin* gene and *YAP-1* gene expression. The remaining part was put in plain tube and left to stand for 10 min then centrifuged for 10 min at 4000 RPM. The supernatant serum was put into several aliquots and stored at -80 to until used for determination of liver function tests and tumor markers including AFP and CEA measurement by enzyme linked immunosorbent assay (ELISA - DRG International Inc., USA.) and detection of HCV-RNA presence by real-time polymerase chain reaction using COBAS TaqMan HCV quantitative test, version 2.0 (Roche Molecular Systems, Inc., Branchburg, NJ, USA) ([@bib11]).

2.1. RNA extraction and quantitative real time PCR assay of *Livin* and *YAP1* genes {#sec2.1}
------------------------------------------------------------------------------------

Total RNA was isolated from whole blood using (The Invitrogen PureLink RNA Mini Kit), according to the manufacturer\'s\' protocol. RNA quantification was conducted by Gene Quant II (Pharmacia Biotech) at 260 nm. Total RNA was stored at -80 °C until molecular investigation was performed. 1 μg of total RNA from each sample was used for cDNA generation in a final reaction volume of 20 μl with High Capacity cDNA Archive Kit (Applied Biosystems).

**The cDNA amplification by real-time PCR**: The cDNA was used in SYBR green based quantitative real-time PCR for quantification of *YAP1* and *Livin* gene expression by (SensiFAST TM SYBR Lo-ROX Kit, Bioline), using the designed primers (Midland,TX). As shown in [Table](#dtbla){ref-type="table"}A PCR was conducted under the following conditions: 95 °C for 10 min, then 40 cycles; denaturation at 94 C for 15 s, annealing at 60 C for 30 s and extension at 72 C for 30 s. Data analysis with Applied Biosystems 7500 software version 2.0.1 was carried out. The relative quantification (RQ) of gene expression completed using comparative ΔΔCt method where the amount of the target *Livin* gene and YAP 1 gene, are normalized to an endogenous reference gene (*GAPDH)* and relative to a control. Each run was completed using melting curve analysis to confirm specificity of the amplification and absence of primer dimers ([@bib21]).[Fig. 1](#fig1){ref-type="fig"}a shows the amplification plot and melting curve of *Livin* gene expression. While [Fig. 1](#fig1){ref-type="fig"}b shows the amplification plot and melting curve of *YAP1* gene expression.Table APrimers used for detection of *YAP1* gene and *Livin* gene.Table AgenePrimerAccession number*YAP1* geneForward TAGCCCTGCGTAGCCAGTTA\
Reverse TCATGCTTAGTCCACTGTCTGTNM_001130145.3*Livin* geneForward TGAGGAGTTGCGTCTGG\
Reverse GCACGGCACAAAGACGATNM_139317.3*GAPDH*Forward TGCACCACCAACTGCTTAGC\
Reverse GGCATGGACTGTGGTCATGAGNM_002046.7Fig. 1(a): Amplification plot and melting curve of *Livin* gene expression. (b): Amplification plot and melting curve of *YAP1* gene expression.Fig. 1

2.2. Statistical methods {#sec2.2}
------------------------

Data collected was analyzed using SPSS version 23 computer statistical software package. The results were expressed as mean ± SD. The **ANOVA** F test was used to determine significant difference between test and control subjects.**Kruskal Wallis test,** Pairwise comparison between each 2 groups was done using Post Hoc Test (Dunn\'s test) for multiple comparisons test). Spearman coefficient was done for correlation between different studied parameters in each subject group. Cox regression of overall survival in HCC group was done for determination of hazard ratio. Statistical significance level was considered when p \< 0.05.

3. Results {#sec3}
==========

120 subjects were included in these study 90 patients and 30 healthy controls with 30 subjects in each of the studied group. No statistical significant difference was detected between different studied groups regarding demographic data or risk factors ([Table 1](#tbl1){ref-type="table"}).Table 1Comparison between the different studied groups according to demographics data and risk factors.Table 1HCC (n = 30)HCV no treatment (n = 30)HCV with treatment (n = 30)Control (n = 30)Test of Sig.pNo.%No.%No.%No.%**Gender**Male2686.72066.72480.01860.0χ^2^ = 6.8180.078Female413.31033.3620.01240.0**Age (years)**Min. -- Max.35.0--65.019.0--70.038.0--68.030.0--68.0F = 2.4590.066Mean ± SD.51.03 ± 7.6449.77 ± 16.3456.87 ± 7.8349.47 ± 14.0Median53.055.056.045.0**Risk factors**Smoking1343.31240.0723.3620.05.7000.127Diabetes1446.7723.3826.71446.76.1980.102Hypertension1033.3516.7516.7826.73.3540.340[^1]

A high statistical significant difference was detected between the three studied groups and between all studied groups and control group regarding relative quantitation (RQ) of *Livin* and *YAP1* genes expression levels with highest level was in HCC group followed by HCV untreated group then HCV treated group and control with median (8.76, 4.33, 0.78 and 0.78) of *Livin* gene and median of (9.42, 4.62, 4.70 and 0.55) in YAP 1 gene ([Table 2](#tbl2){ref-type="table"} & [Fig. 2](#fig2){ref-type="fig"}).Table 2Comparison between the different studied groups according to RQ.Table 2HCC (n = 30)HCV no ttt (n = 30)HCV w ttt (n = 30)Control (n = 30)Hp**RQ of *Livin* gene**Min. -- Max.3.54--25.671.89--8.200.43--4.250.43--4.2595.201[∗](#tbl2fnlowast){ref-type="table-fn"}\<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}Mean ± SD.9.52 ± 4.484.30 ± 1.450.94 ± 0.721.04 ± 0.93Median8.764.350.780.78**p~1~**\<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}\<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}0.873**Sig. bet. Grps**p~2~ = 0.002[∗](#tbl2fnlowast){ref-type="table-fn"},p~3~ \< 0.001[∗](#tbl2fnlowast){ref-type="table-fn"},p~4~ \< 0.001[∗](#tbl2fnlowast){ref-type="table-fn"}**RQ of *YAP1* gene**Min. -- Max.4.75--40.680.04--15.701.28--10.500.02--1.1077.131\<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}Mean ± SD.14.06 ± 10.843.98 ± 3.855.16 ± 2.440.51 ± 0.29Median9.424.644.700.55**p~1~**\<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}\<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}\<0.001[∗](#tbl2fnlowast){ref-type="table-fn"}**Sig. bet. Grps**p~2~ \< 0.001[∗](#tbl2fnlowast){ref-type="table-fn"},p~3~ = 0.001[∗](#tbl2fnlowast){ref-type="table-fn"},p~4~ = 0.112[^2][^3][^4][^5][^6][^7][^8]Fig. 2Comparison between the different studied groups according to RQ of *Livin* and *YAP1* genes.Fig. 2

Correlation between RQ of *Livin* gene expression and laboratory investigations in each group was estimated using Spearman coefficient method and the following were concluded from the results: there was a significant positive coefficient correlation between RQ of *Livin* gene expression with RQ of *YAP1* gene expression, serum CEA and albumin levels in HCC group, while in HCV untreated group there was a significant coefficient negative association between RQ of *Livin* gene expression with serum creatinine level, Blood Urea Nitrogen (BUN)and INR level, also positive coefficient association was found between RQ of *Livin* gene expression and AFP serum level in HCV with treatment group (p \< 0.05) ([Table 3](#tbl3){ref-type="table"}).Table 3Correlation between RQ of *Livin* gene expression and laboratory investigation & RQ of *YAP1* gene expression in each group.Table 3RQ of *Livin* gene expressionHCCHCV no tttHCV w tttControlr~s~pr~s~pr~s~pr~s~pTLC (x103/ul)-0.2590.1680.1180.5350.1230.5160.0520.784Platelets (x10^3^/ul)-0.0030.986-0.1400.459-0.0190.921-0.0370.848Prothrombin time percent-0.1460.4430.1480.4350.1260.5080.0690.718INR0.0850.653-0.482[∗](#tbl3fnlowast){ref-type="table-fn"}0.007[∗](#tbl3fnlowast){ref-type="table-fn"}-0.2810.133-0.0260.891ALT (IU/L)0.2170.248-0.3450.0620.0110.9540.2120.260AST (IU/L)0.0590.757-0.1950.302-0.2150.2530.0730.701ALP (IU/L)0.1380.468-0.0670.724-0.1310.491-0.0600.755GGT (IU/L)-0.3660.046-0.1030.589-0.0900.636-0.1100.563AFP (ng/ml)0.3580.0520.1630.3910.449[∗](#tbl3fnlowast){ref-type="table-fn"}0.013[∗](#tbl3fnlowast){ref-type="table-fn"}-0.2110.264CEA (mg/dl)0.392[∗](#tbl3fnlowast){ref-type="table-fn"}0.032[∗](#tbl3fnlowast){ref-type="table-fn"}-0.2810.133-0.3570.0530.0930.625Albumin (gm/dl)0.451[∗](#tbl3fnlowast){ref-type="table-fn"}0.012[∗](#tbl3fnlowast){ref-type="table-fn"}0.2870.124-0.2260.2310.0730.701Total bilirubin (mg/dl)-0.1190.531-0.1150.5440.0630.7400.1840.330Direct bilirubin (mg/dl)0.1700.370-0.2730.1450.1610.395-0.0950.618BUN (mg/dl)-0.0530.779-0.503[∗](#tbl3fnlowast){ref-type="table-fn"}0.005[∗](#tbl3fnlowast){ref-type="table-fn"}0.3050.101-0.0110.955Creatinine (mg/dl)-0.3200.084-0.438[∗](#tbl3fnlowast){ref-type="table-fn"}0.016[∗](#tbl3fnlowast){ref-type="table-fn"}0.0210.9130.2220.237RQ of *YAP1* gene expression0.6800.0010.0246[∗](#tbl3fnlowast){ref-type="table-fn"}0.8970.14150.45570.1960.299[^9][^10]

The correlation of RQ of livin and YAP1 gene expression and viral load: there was a non significant correlation between viral load and both livin and yap1 gene expression in all groups (not shown).

The Correlation between RQ of *YAP1* gene expression and laboratory investigations in each group was estimated with the following results: there was a significant positive coefficient correlation between RQ of *YAP1* gene expression with serum CEA level in HCC group and negative association in HCV untreated group which demonstrated also a coefficient negative association between RQ of *YAP1* gene expression with platelet count and positive association with prothrombin time. No association was found between RQ of YAP 1 gene expression with any of the studied parameters in HCV with treatment group and control group ([Table 4](#tbl4){ref-type="table"} & [Fig. 3](#fig3){ref-type="fig"}).Table 4Correlation between RQ of *YAP1* gene and laboratory investigation in each group.Table 4RQ of *YAP1* geneHCCHCV no tttHCV w tttControlr~s~pr~s~pr~s~pr~s~pTLC (x10^3^/ul)-0.1370.471-0.0240.8980.1350.478-0.3590.051Platelets (x10^3^/ul)0.1300.493-0.528[∗](#tbl4fnlowast){ref-type="table-fn"}0.003[∗](#tbl4fnlowast){ref-type="table-fn"}0.3020.105-0.2690.151Prothrombin time percent0.0350.8560.561[∗](#tbl4fnlowast){ref-type="table-fn"}0.001[∗](#tbl4fnlowast){ref-type="table-fn"}-0.1840.331-0.1340.480INR0.0120.949-0.3500.0580.2020.2860.0450.813ALT (IU/L)0.3410.065-0.0690.716-0.0280.883-0.0040.984AST (IU/L)0.2440.194-0.0850.6560.0300.877-0.2630.160ALP (IU/L)0.3800.0380.0170.9300.1420.453-0.3480.060GGT (IU/L)-0.3310.0740.0660.728-0.2480.1860.1900.314AFP (ng/ml)0.3080.0970.2900.120-0.1820.335-0.0260.892CEA (mg/dl)0.711[∗](#tbl4fnlowast){ref-type="table-fn"}\<0.001[∗](#tbl4fnlowast){ref-type="table-fn"}-0.606[∗](#tbl4fnlowast){ref-type="table-fn"}\<0.001[∗](#tbl4fnlowast){ref-type="table-fn"}0.3290.0760.1330.483Albumin (gm/dl)0.4020.028-0.1200.529-0.0300.877-0.2630.160Total bilirubin (mg/dl)-0.1710.3670.1990.2910.1950.302-0.2020.284Direct bilirubin (mg/dl)0.0590.758-0.0310.8700.1000.5980.2060.275BUN (mg/dl)-0.0870.6460.0300.874-0.2000.2900.2530.177Creatinine (mg/dl)-0.0990.604-0.0350.856-0.1710.365-0.0260.892[^11][^12]Fig. 3Correlation between RQ of *Livin* and *YAP1* genes and CEA (mg/dl) in HCC group.Fig. 3

There was a significant difference between the RQ of *Livin* and *YAP1* genes expression levels with different tumor size detected by ultrasound (US) in HCC group with the highest levels in multifocal lesion, followed by tumor of diameter larger than 5 cm ([Table 5](#tbl5){ref-type="table"} & [Fig. 4](#fig4){ref-type="fig"}).Table 5Relation between RQ of *Livin* gene and RQ of *YAP1* gene with tumor size by US in HCC group (n = 30).Table 5Tumor size by USNRQ of *Livin* geneHpMin. -- Max.Mean ± SD.Median ≤5143.54--9.937.13 ± 1.837.0111.644[∗](#tbl5fnlowast){ref-type="table-fn"}0.003[∗](#tbl5fnlowast){ref-type="table-fn"} \>595.67--20.8011.37 ± 4.4511.53 Multifocal77.56--25.6711.92 ± 6.1810.39Tumor size by USNRQ of *YAP1* geneHpMin. -- Max.Mean ± SD.Median ≤5144.75--11.896.94 ± 1.966.4515.622[∗](#tbl5fnlowast){ref-type="table-fn"}\<0.001[∗](#tbl5fnlowast){ref-type="table-fn"} \>5**9**6.25--36.8918.35 ± 11.6813.78 Multifocal**7**9.89--40.6822.79 ± 11.9424.67[^13][^14][^15]Fig. 4Relation between RQ of *Livin* and YAP1 genes and tumor size in HCC group.Fig. 4

The CEA level, RQ of *Livin* and *YAP1* genes expression levels can be considered as a bad sign for overall survival in HCC patients by univariate analysis, while by multivariate analysis only RQ of *YAP1* gene expression can be considered as bad sign for overall survival in HCC patients ([Table 6](#tbl6){ref-type="table"}).Table 6Cox regression of overall survival in HCC group for determination of hazard ratio.Table 6Univariate[\#](#tbl6fnhash){ref-type="table-fn"}MultivariatepHR (95%C.I)pHR (95%C.I)Gender (female)0.4421.887 (0.400--8.892)Age (years)0.9600.998 (0.923--1.079)Smokin0.7120.788 (0.222--2.796)Diabetes0.6160.724 (0.204--2.564)Hypertension0.4631.607 (0.453--5.701)Hb level (gm/dl)0.3831.158 (0.833--1.608)TLC (x103/ul)0.9290.984 (0.685--1.412)Platelets (x103/ul)0.6871.002 (0.992--1.012)Prothrombin time percent0.8751.004 (0.960--1.049)INR0.9510.908 (0.044--18.963)ALT (IU/L)0.6101.007 (0.980--1.035)AST (IU/L)0.8451.003 (0.973--1.033)ALP (IU/L)0.9481.000 (0.991--1.008)Albumin (gm/dl)0.1132.133 (0.837--5.437)GGT (IU/L)0.2740.996 (0.988--1.004)AFP (ng/ml)0.8831.000 (0.999--1.001)CEA (mg/dl)0.023[∗](#tbl6fnlowast){ref-type="table-fn"}1.074 (1.010--1.142)0.6290.964 (0.829--1.120)Total bilirubin (mg/dl)0.0940.149 (0.016--1.383)Direct bilirubin (mg/dl)0.2180.067 (0.001--4.954)BUN (mg/dl)0.9691.002 (0.928--1.081)Creatinine (mg/dl)0.2300.294 (0.040--2.168)PCR x10^5^0.0881.002 (1.000--1.004)RQ of *Livin* gene0.008[∗](#tbl6fnlowast){ref-type="table-fn"}1.168 (1.402--1.308)0.4380.914 (0.728--1.147)RQ of *YAP1* gene\<0.001[∗](#tbl6fnlowast){ref-type="table-fn"}1.124 (1.065--1.186)0.001[∗](#tbl6fnlowast){ref-type="table-fn"}1.196 (1.078--1.328)[^16][^17][^18]

4. Discussion {#sec4}
=============

Despite great advances in diagnosis and treatment of HCC, the mortality rate is still high, especially in advanced stage. This indicates that a great effort is needed to identify novel prognostic markers and to develop new therapeutic strategies ([@bib33]).

*Livin* is a member of the inhibitors of apoptosis proteins family, it plays a vital role in the regulation of apoptosis with subsequent modulation of cell cycle and cell proliferation. *Livin* is over-expressed in several cancer types, its anti-apoptotic activity is mediated mostly by the direct inhibition of caspase 3, 7 and 9 ([@bib2]). Our study proved that *Livin* gene was found to be significantly overexpressed in hepatocellular carcinoma patients, similar results were demonstrated by other authors ([@bib5]). *Livin* gene expression was also reported by many authors to be elevated in a number of other tumors like adrenocortical tumors, colorectal tumors ([@bib23])& ([@bib30])superficial bladder cancer tumors ([@bib10])neuroblastoma ([@bib17])acute lymphoblastic leukemia ([@bib6]) and melanoma as well as many other types of tumors ([@bib18]).

Many studies concluded that IAP members as *Livin* gene represent attractive molecular targets for the design of new classes of anticancer drugs which can give promising results for treatment of many cancer patients ([@bib29]) ([@bib26]). However, the expression of this protein in many normal tissues may represent a challenge for its role in cancer therapy and represent a lot of side effects like nephrotoxicity, infertility and gastrointestinal disorders ([@bib7]).

*YAP1*is a well-known oncogenic protein in human cancer ([@bib14]). It is a transcriptional regulator and it plays a pivotal role in organ size control ([@bib34]). In HCC, *YAP1* was found to be overexpressed and could promote the growth and metastasis of HCC cells ([@bib9]).

In our study significant overexpression of YAP-1 was detected in HCC patients as well as patients with HCV confirming the results which were reported by many other previous studies ([@bib31]) ([@bib32]) ([@bib35]).

Correlation between RQ of both *Livin* gene and *YAP1* expression and laboratory investigations in each group was estimated using Spearman coefficient method and there was a significant positive coefficient correlation between both RQ of *Livin* and YAP1 gene expression, RQ of *Livin* gene expression with serum CEA in HCC group also between RQ of *YAP1* gene expression with serum CEA level in HCC group, this finding when added to the result that There was a significant difference between the RQ of *Livin* and *YAP1* genes expression levels with different tumor size detected by US in HCC group with the highest levels in multifocal lesion, followed by tumor of diameter larger than 5 cm indicating that *Livin* and *YAP1* genes are associated with HCC and indicating bad prognosis of the disease. Previous findings were reported by other studies like Fan et al.who concluded that an increased expression of YAP-1 within PBMCs could serve as a bad indicator for the prognosis of HCC patients as that study reported high level of *YAP1* in mononuclear cells and showed positive linear correlation to Treg percentage which is immunosuppressant cells ([@bib8]*)*.

The CEA level, RQ of *Livin* and *YAP1* genes expression levels can be considered as bad signs for overall survival in HCC patients by univariate Cox regression analysis while by multivariate analysis only RQ of *YAP1* gene expression can be considered as a bad sign for overall survival in HCC patients. This finding confirms what obtained by [@bib36] who demonstrated that high level of YAP 1 together with low level of miRNA-345 was associated with low survival rate. Otherstudy also reported that YAP-1 is associated with increased) TGF-β(within HCC and hyperplasia of oval cells together with activation of inflammatory cell infiltration and fibrosis ([@bib24]).

IHC studies on human HCC samples showed that elevated expression of YAP correlates with poor tumor differentiation and is prognostic of bad outcome ([@bib13]). YAP protein levels are upregulated starting from precancerous lesions, but overt nuclear localization of YAP can be found only in fully developed HCC and CC ([@bib25]).

*Livin* gene expression was also reported as a bad prognostic marker by [@bib4] who concluded that *Livin* overexpression in HCC patients imply that its level could be used as a marker of cancer tissue and more importantly, could be related with patients\' survival.

Also, the study of Hua [@bib12] found that Livin protein expression was significantly higher in HCC tissues than that in normal hepatic tissues and hepatitis/hepatic cirrhosis tissues, with no significant difference between HCC tissues and pericarcinoma tissues.

YAP can also induce the expression of several negative regulators of apoptosis such as the inhibitors of apoptosis proteins (IAP) family members baculoviral IAP repeat containing *5 (BIRC5*)/survivin and *BIRC2*/cIAP1 and the B-cell lymphoma-2 (BCL2) family gene myeloid cell leukemia-1 (*MCL1*). Thus, YAP can act as potent inhibitor of apoptosis in the regulation of organ size ([@bib27]).

5. Conclusions {#sec5}
==============

Based on the findings in our study, we concluded that there is overexpression of *Livin* and YAP 1 genes in hepatocellular carcinoma patients and HCV patients. So they can be used as indicators of bad prognosis of the disease pathway together with low survival rate in HCC patients. Future studies should focus on their patho -physiological role in progress of HCC as well as in other cancer types in order to develop new therapeutic choices. However, there are some limitations in the current study; limited sample sizes together with that serum samples were not correlated with expressed levels of investigated gene expression, also IHC staining of livin and yap1 in the patient samples could help. a HCC group without HCV infection can be used as a reference group to confirm that the change of livin and YAP1 expression is due to HCC cancer alone or HCV or both.
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[^1]: χ^2^: **Chi square testF**: **F for ANOVA test**p: p value for comparing between the studied groups.

[^2]: H: H for **Kruskal Wallis test,** Pairwise comparison bet. each 2 groups was done using **Post Hoc Test (Dunn\'s for multiple comparisons test)**.

[^3]: p: p value for comparing between the studied groups.

[^4]: p~1~: p value for comparing between control and each other groups.

[^5]: p~2~: p value for comparing between HCC group and HCV no ttt group.

[^6]: p~3~: p value for comparing between HCC group and HCV w ttt group.

[^7]: p~4~: p value for comparing between HCV no treatment group and HCV with treatment.

[^8]: Statistically significant at p ≤ 0.05.

[^9]: r~s~: Spearman coefficient.

[^10]: Statistically significant at p ≤ 0.05.

[^11]: r~s~: Spearman coefficient.

[^12]: Statistically significant at p ≤ 0.05.

[^13]: H: H for Kruskal Wallis test.

[^14]: p: p value for comparing between the different categories.

[^15]: Statistically significant at p ≤ 0.05.

[^16]: OR: Odd\'s ratio, C.I: Confidence interval.

[^17]: All variables with p \< 0.05 was included in the multivariate.

[^18]: Statistically significant at p ≤ 0.05.
